TATA Health International Holdings Limited Announces Completion of Discloseable Transaction: Disposal of Target Company

Key Highlights:

• Disposal of Target Company Completed: On 13 March 2026, TATA Health International Holdings Limited successfully completed the disposal of its target company. This transaction is classified as a discloseable transaction under the rules of the Hong Kong Stock Exchange.
• Release of Security Interests: Upon completion, the floating charge over inventories of Grand Asian Limited (an indirect wholly-owned subsidiary) has been released and discharged.
• Change in Subsidiary Ownership: KTS HK, previously a direct wholly-owned subsidiary of the Target Company, is now an indirect wholly-owned subsidiary of the Purchaser (who was also the lender of KTS HK).
• Security Interests Over Group Assets: The charges over the properties and receivables of KTS HK no longer affect the TATA Health Group after the disposal.

Details of the Transaction

The Purchaser was previously a lender who provided a HK\$20,000,000 credit facility to KTS HK, which was secured by:

• A legal charge over properties held by KTS HK,
• A floating charge over inventories of Grand Asian Limited,
• A floating charge over receivables of KTS HK.

Following the completion of the disposal:

• The floating charge over the inventories of Grand Asian Limited was released and discharged, strengthening the Group’s financial and operational flexibility.
• KTS HK became an indirect wholly-owned subsidiary of the Purchaser, removing any further impact of charges over KTS HK’s properties and receivables on TATA Health’s Group.

Shareholder Implications and Price Sensitive Information

• Improved Financial Position: The release of the floating charge over Grand Asian Limited’s inventories reduces potential liabilities and risks associated with pledged assets, which may positively impact the Group’s balance sheet and risk profile.
• Group De-risking: The transfer of KTS HK and the associated security interests out of the Group means the Group is no longer exposed to risks or obligations relating to the properties and receivables of KTS HK.
• Potential Share Price Impact: Investors may view the disposal and the release of encumbrances on Group assets favorably, as it strengthens the Group’s financial flexibility and reduces secured liabilities—developments that could influence the share price.

Board Composition

As of the date of the announcement, the Board comprises:

• Executive Director: Mr. Zhang Ming Qi
• Non-executive Directors: Mr. Chu Chun Ho, Dominic and Mr. Chen Qi
• Independent Non-executive Directors: Ms. Huang Lin, Mr. Li Liang, Mr. Du Jianfeng, and Mr. Tan Kaiguo

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult financial advisors before making investment decisions. The Company and the writer do not accept any liability for losses incurred from reliance on the information provided herein.

View TATA HEALTH Historical chart here